A large number of different, already existing and approved drugs are currently being tested for the treatment of infections with the SARS-CoV-2 virus. These include, for example, antiviral drugs, immune modulators and drugs for lung diseases. In addition, research is being carried out on completely new active ingredients that are currently not approved as medicinal products.
Due to the large number of active ingredients currently in question which are pharmacologically and chemically very different, no statement can be made at this time to what extent potential future drugs for the treatment of COVID-19 are or will be part of the current or future WADA prohibited lists. A binding assessment can only be made if the specific active substance to be used is known.